ArticleRadiology. Imaging cancer2025
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study.
Abstract read
In one paragraph
Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Baseline PSMA tumor volume as a prognostic marker in radical radiotherapy for prostate cancer: a propensity score-weighted retrospective analysis.Annals of nuclear medicine · 2026Article
- PSMA-guided management of recurrent post-prostatectomy patients: a sub-analysis of a prospective single-center study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Francesco LanfranchiDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.ORCID 0000-0002-6043-9627
Liliana BelgioiaDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Domenico AlbanoDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Luca TriggianiDepartment of Radiation Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Flavia LinguantiDepartment of Nuclear Medicine, Careggi University Hospital, Florence, Italy.
Luca UrsoNuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
Rosario MazzolaAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Verona, Italy.
Alessio RizzoDepartment of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Elisa D'AngeloDepartment of Radiation Oncology, University Hospital of Modena, Modena, Italy.
Francesco DondiDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Eneida MatajDepartment of Radiation Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Gloria PedersoliDepartment of Radiation Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Elisabetta Maria AbenavoliDepartment of Radiation Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Luca VaggelliDepartment of Nuclear Medicine, Careggi University Hospital, Florence, Italy.
Beatrice DettiDepartment of Radiation Oncology, Careggi University Hospital, Florence, Italy.
Naima OrtolanNuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
Antonio MalorgioDepartment of Radiotherapy, University Hospital of Ferrara, Ferrara, Italy.
Alessia GuarneriDepartment of Radiation Oncology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Federico GarrouDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Matilde FioriniAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Verona, Italy.
Serena GrimaldiDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.ORCID 0000-0002-9549-5004
Pietro GhediniDepartment of Nuclear Medicine, Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Giuseppe Carlo IorioDepartment of Oncology, Radiation Oncology, University of Turin, Turin, Italy.
Antonella IudicelloDepartment of Nuclear Medicine, Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Guido RoveraDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Giuseppe FornariniDepartment of Medical Oncology 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Diego BongiovanniDepartment of Oncology, Radiation Oncology, University of Turin, Turin, Italy.
Michela MarcenaroDepartment of Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Filippo Maria PazienzaDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Giorgia TimonDepartment of Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Matteo SalgarelloDepartment of Nuclear Medicine, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy.ORCID 0000-0002-1937-9116
Manuela RaccaDepartment of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Mirco BartolomeiNuclear Medicine, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, Italy.
Stefano PanareoDepartment of Nuclear Medicine, Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Umberto RicardiDepartment of Oncology, Radiation Oncology, University of Turin, Turin, Italy.
Francesco BertagnaDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Filippo AlongiAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Verona, Italy.
Salvina BarraDepartment of Radiotherapy, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Silvia MorbelliDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Gianmario SambucetiDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Matteo BaucknehtDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prospective trials suggest that metastasis-directed therapy (MDT) is an effective treatment for patients with oligometastatic prostate cancer (PCa). Gallium 68 (
Indexed as
Neoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiopharmaceuticalsAgedAged, 80 and overCholineFluorine RadioisotopesGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm MetastasisNiacinamideOligopeptidesCholineFluorine Radioisotopesfluorocholinegallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesNiacinamideOligopeptidesPSMA-1007RadiopharmaceuticalsOncologyPET/CTProstateRadiation TherapyUrinary
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.